U.S. Patent No. 10,155,018 B1 (‘018) issued on December 18, 2018, for “Method of Improving Sexual Response and Sensitivity.” It was issued to applicant/inventor Dennis M. Jenn of South Jordan, Utah. The assignee is Ilysm, LLC of Murray, Utah. Ilysm appears to be a startup company focused on cannabis-based sexual performance enhancement compositions.
The ‘018 patent discloses pharmaceutical compounds to enhance sexual activity. These compounds can include both tetrahydrocannabinol (THC) and cannabidiol (CBD) in varied ratios in combination with any of the three major erectile dysfunction (ED) pharmaceutical drugs currently on the market – sildenafil (VIAGRA®), tadalafil (CIALIS®), or vardenafil (LEVITRA®). The claims are directed to methods of treating ED through these disclosed compounds in oral administered form (i.e., pill), between 10-250 mg of both THC and CBD. In the specification, the stated problem is the lack of remedy for lost sensitivity during sexual activity, for which the novel aspect of this invention addresses. The claimed invention, therefore, would be an improvement over the these conventional pharmaceutical products because it contains cannabinoids from both the C. sativa and C. indica plants. The specification’s disclosed embodiments are thirteen case studies of the product’s effectiveness of these patients.
The Cooperative Patent Classifications are A61K (preparations for medical, dental purposes, namely traditional herbal medicinal product containing magnoliopsida (36/185); A23L (foods, foodstuffs, or non-alcoholic beverages, namely synthetic spices, flavoring agents or condiments having oxygen or sulfur as the only hetero atoms (27/2052)); A21D (preservation treatment namely products characterized by type, form or use (13/40)); and A23C (dairy products, namely butter preparations (15/12)).
This is yet another interesting patent involving cannabis-based products. Please contact Yonaxis for more information on any of the IP processes described in this posting if you have any questions.